Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke (GDPRS)
A Randomized, Active-Controlled，Blinded-Endpoint and Parallel Group Pilot Trial Comparing the Antiplatelet Effects of Ginkgo Diterpene Lactone Meglumine Injection Plus Aspirin Versus Aspirin Alone in Patients With Acute Ischemic Stroke
Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd
This PHASE2/PHASE3 trial investigates Ischemic Stroke and is currently ongoing. Jiangsu Kanion Pharmaceutical Co., Ltd leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
Aug 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Kanion Pharmaceutical Co., Ltd
- RenJi Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.